We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875.